Enhanced generation of adherent lymphokine-activated killer...

Details Enhanced generation of adherent lymphokine-activated killer... Enhanced generation of adherent lymphokine-activated killer...

C - Chemistry, Metallurgy

12

N

C12N 5/06 (2006.01) A61K 35/14 (2006.01) A61K 38/20 (2006.01) A61K 35/12 (2006.01)

Patent

CA 2060278

BT-0061 TITLE Enhanced Generation of Adherent Lymphokine-activated Killer Cells with Interleukin-2 and Interleukin-4 from L-phenylalanine Methyl Ester-treated Human Pexipheral Blood Cells ABSTRACT OF THE INVENTION Peripheral blood mononuclear cells (PBMC) are treated to deplete monocytes and the remaining cells are cultured in a medium containing interleukin-2 (IL-2) without interleukin-4 (IL-4). Nonadherent cells are removed and discarded, and adherent cells are further cultured in a medium of IL-2 and IL-4 which expands the A-LAK cell population of the PBMC. The expanded, enriched A-LAK cells can be placed in a pharmaceutically acceptable carrier and administered to a mammal with IL- 2 to treat a tumor.

Affiliated with

Also associated with

Rating

Enhanced generation of adherent lymphokine-activated killer... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Enhanced generation of adherent lymphokine-activated killer..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhanced generation of adherent lymphokine-activated killer... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1832231